Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Feb-24 5:51 PM View:  | Scopa James Paul Director | Adverum Biotechnologies, Inc. (ADVM) | 07-Feb-24 | Private Purchase | 100,000 | $1.35 | $135,000.00 | 2999% 3.33K to 103.33K | |
| 09-Feb-24 5:50 PM View: | Lupher, Jr. Mark L. Director | Adverum Biotechnologies, Inc. (ADVM) | 07-Feb-24 | Private Purchase | 130,000 | $1.35 | $175,500.00 | 100% 0 to 130.0K | |
| 18-Sep-23 6:54 PM View: | Seyedkazemi Setareh Chief Development Officer | Adverum Biotechnologies, Inc. (ADVM) | 15-Sep-23 | Sale | 6,201 | $1.52 | $9,429.24 | (12%) 53.88K to 47.67K | |
| 09-Jun-23 4:26 PM View: | Rubinstein Linda M Chief Financial Officer | Adverum Biotechnologies, Inc. (ADVM) | 07-Jun-23 | Private Purchase | 100,000 | $1.45 | $145,490.00 | 100% 0 to 100.0K | |
| 17-Mar-23 6:02 PM View: | Riley Brigit Chief Scientific Officer | Adverum Biotechnologies, Inc. (ADVM) | 15-Mar-23 | Sale | 7,299 | $0.78 | $5,704.90 | (6%) 124.73K to 117.44K | |
| 17-Mar-23 6:01 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Mar-23 | Sale | 41,239 | $0.78 | $32,232.40 | (6%) 733.38K to 692.14K | |
| 17-Mar-23 6:02 PM View: | Soparkar Peter Chief Operating Officer | Adverum Biotechnologies, Inc. (ADVM) | 15-Mar-23 | Sale | 13,360 | $0.78 | $10,442.20 | (5%) 279.25K to 265.89K | |
| 21-Sep-22 7:57 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 19-Sep-22 | Sale | 41,082 | $1.07 | $43,941.30 | (5%) 768.46K to 727.38K | |
| 21-Sep-22 7:59 PM View: | Soparkar Peter See Remarks section | Adverum Biotechnologies, Inc. (ADVM) | 19-Sep-22 | Sale | 13,305 | $1.07 | $14,232.40 | (5%) 286.56K to 273.25K | |
| 21-Sep-22 8:00 PM View: | Seyedkazemi Setareh Chief Development Officer | Adverum Biotechnologies, Inc. (ADVM) | 19-Sep-22 | Sale | 6,058 | $1.07 | $6,479.64 | (11%) 53.93K to 47.88K | |
| 21-Sep-22 8:01 PM View: | Beckman Richard Chief Medical Officer | Adverum Biotechnologies, Inc. (ADVM) | 19-Sep-22 | Sale | 4,272 | $1.07 | $4,569.76 | (10%) 43.33K to 39.06K | |
| 21-Sep-22 7:58 PM View: | Riley Brigit Chief Scientific Officer | Adverum Biotechnologies, Inc. (ADVM) | 19-Sep-22 | Sale | 7,266 | $1.07 | $7,772.44 | (6%) 126.0K to 118.73K | |
| 16-Sep-22 7:25 PM View: | Seyedkazemi Setareh Chief Development Officer | Adverum Biotechnologies, Inc. (ADVM) | 14-Sep-22 | Grant | 33,333 | -- | -- | 162% 20.6K to 53.93K | |
| 16-Sep-22 7:26 PM View: | Beckman Richard Chief Medical Officer | Adverum Biotechnologies, Inc. (ADVM) | 14-Sep-22 | Grant | 25,000 | -- | -- | 250% 10.0K to 35.0K | |
| 24-May-22 4:47 PM View: | Seyedkazemi Setareh Chief Development Officer | Adverum Biotechnologies, Inc. (ADVM) | 23-May-22 | Private Purchase | 20,000 | $0.84 | $16,800.00 | 3333% 0.6K to 20.6K | |
| 17-May-22 6:28 PM View: | d'Souza Rupert Chief Financial Officer | Adverum Biotechnologies, Inc. (ADVM) | 17-May-22 | Purchase | 10,000 | $0.83 | $8,272.00 | 92% 10.85K to 20.85K | |
| 19-May-22 7:43 PM View: | Beckman Richard Chief Medical Officer | Adverum Biotechnologies, Inc. (ADVM) | 17-May-22 | Private Purchase | 10,000 | $0.82 | $8,228.00 | 100% 0 to 10.0K | |
| 18-May-22 4:43 PM View: | Graham Dawn Director | Adverum Biotechnologies, Inc. (ADVM) | 16-May-22 | Private Purchase | 30,000 | $0.85 | $25,578.00 | 150% 20.0K to 50.0K | |
| 17-May-22 6:28 PM View: | d'Souza Rupert Chief Financial Officer | Adverum Biotechnologies, Inc. (ADVM) | 13-May-22 | Private Purchase | 10,000 | $0.86 | $8,585.00 | 1176% 0.85K to 10.85K | |
| 22-Apr-22 5:00 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 20-Apr-22 | Private Purchase | 25,000 | $1.11 | $27,800.00 | 3% 737.46K to 762.46K | |
| 20-Apr-22 4:35 PM View: | Soparkar Peter See Remarks section | Adverum Biotechnologies, Inc. (ADVM) | 19-Apr-22 | Private Purchase | 21,925 | $1.14 | $24,994.00 | 8% 258.63K to 280.56K | |
| 10-Dec-21 5:26 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 09-Dec-21 | Market Purchase | 14,323 | $1.85 | $26,497.60 | 2% 723.14K to 737.46K | (< 1%) |
| 10-Dec-21 5:26 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 08-Dec-21 | Market Purchase | 10,677 | $1.79 | $19,111.80 | 1% 712.46K to 723.14K | 3% |
| 10-Dec-21 5:26 PM View: | Soparkar Peter See Remarks section | Adverum Biotechnologies, Inc. (ADVM) | 08-Dec-21 | Market Purchase | 25,000 | $1.91 | $47,750.00 | 11% 233.63K to 258.63K | (4%) |
| 17-Nov-21 4:38 PM View: | Scopa James Paul Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Nov-21 | Market Sale | 50,000 | $2.18 | $109,000.00 | (94%) 53.33K to 3.33K | 1% |
| 04-Oct-21 5:36 PM View: | Clark Julie Chief Medical Officer | Adverum Biotechnologies, Inc. (ADVM) | 30-Sep-21 | Market Sale | 4,766 | $2.17 | $10,342.20 | (3%) 169.49K to 164.72K | (< 1%) |
| 10-Aug-21 9:26 PM View: | Clark Julie Chief Medical Officer | Adverum Biotechnologies, Inc. (ADVM) | 06-Aug-21 | Grant | 120,000 | -- | -- | 242% 49.49K to 169.49K | |
| 10-Aug-21 9:23 PM View: | Fischer Laurent CEO, President and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 06-Aug-21 | Grant | 680,000 | -- | -- | 2586% 26.29K to 706.29K | |
| 01-Apr-21 8:21 PM View: | Graham Dawn Director | Adverum Biotechnologies, Inc. (ADVM) | 31-Mar-21 | Market Purchase | 20,000 | $10.02 | $200,338.00 | 100% 0 to 20.0K | (2%) |
| 24-Mar-21 7:46 PM View: | MacHado Clarence Patrick Director | Adverum Biotechnologies, Inc. (ADVM) | 24-Mar-21 | Market Purchase | 10,000 | $9.92 | $99,196.00 | 13% 78.18K to 88.18K | (< 1%) |
| 24-Mar-21 7:47 PM View: | Fischer Laurent CEO and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 24-Mar-21 | Market Purchase | 10,000 | $9.88 | $98,780.00 | 61% 16.29K to 26.29K | (< 1%) |
| 11-Feb-21 7:47 PM View: | Patterson Leone D President and CFO | Adverum Biotechnologies, Inc. (ADVM) | 09-Feb-21 | Market Sale | 12,533 | $14.10 | $176,718.00 | (11%) 110.49K to 97.95K | 2% |
| 19-Jan-21 8:32 PM View: | Fischer Laurent CEO and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Jan-21 | Market Purchase | 8,600 | $11.53 | $99,190.70 | 112% 7.69K to 16.29K | (1%) |
| 19-Jan-21 8:33 PM View: | MacHado Clarence Patrick Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Jan-21 | Market Purchase | 10,000 | $11.52 | $115,174.00 | 15% 68.18K to 78.18K | (1%) |
| 16-Dec-20 5:10 PM View: | Woiwode Thomas Director | Adverum Biotechnologies, Inc. (ADVM) | 14-Dec-20 | Acquisition (other) | 12,783 | -- | -- | 212% 6.04K to 18.82K | |
| 19-Aug-20 6:48 PM View: | Soparkar Peter Chief Legal Officer | Adverum Biotechnologies, Inc. (ADVM) | 17-Aug-20 | Market Purchase | 7,692 | $13.00 | $99,996.00 | 256% 3.0K to 10.69K | (< 1%) |
| 19-Aug-20 6:45 PM View: | Fischer Laurent CEO and Director Director | Adverum Biotechnologies, Inc. (ADVM) | 17-Aug-20 | Market Purchase | 7,692 | $13.00 | $99,996.00 | 100% 0 to 7.69K | (< 1%) |
| 22-Jul-20 9:44 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 20-Jul-20 | Option Exercise | 5,000 | $4.80 | $24,000.00 | 2% 274.44K to 279.44K | |
| 22-Jul-20 9:44 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 20-Jul-20 | Market Option Sale (Planned) | 5,000 | $17.60 | $87,978.00 | (2%) 279.44K to 274.44K | 27% |
| 23-Jun-20 6:58 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 22-Jun-20 | Option Exercise | 23,605 | $4.80 | $113,304.00 | 9% 274.44K to 298.05K | |
| 23-Jun-20 6:58 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 22-Jun-20 | Market Option Sale (Planned) | 23,605 | $25.06 | $591,617.00 | (8%) 298.05K to 274.44K | 49% |
| 18-Jun-20 9:45 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 18-Jun-20 | Option Exercise | 11,127 | $4.80 | $53,409.60 | 4% 274.44K to 285.57K | |
| 18-Jun-20 9:45 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 18-Jun-20 | Market Option Sale (Planned) | 11,127 | $25.01 | $278,329.00 | (4%) 285.57K to 274.44K | 48% |
| 18-Jun-20 9:45 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 17-Jun-20 | Option Exercise | 268 | $4.80 | $1,286.40 | < 1% 274.44K to 274.71K | |
| 18-Jun-20 9:45 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 17-Jun-20 | Market Option Sale (Planned) | 268 | $25.01 | $6,702.71 | (< 1%) 274.71K to 274.44K | 48% |
| 17-Jun-20 5:47 PM View: | Patterson Leone D President | Adverum Biotechnologies, Inc. (ADVM) | 16-Jun-20 | Market Sale | 13,171 | $24.68 | $325,060.00 | (11%) 123.66K to 110.49K | 48% |
| 17-Jun-20 5:14 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Jun-20 | Option Exercise | 10,000 | $4.80 | $48,000.00 | 4% 274.44K to 284.44K | |
| 17-Jun-20 5:14 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 15-Jun-20 | Market Option Sale (Planned) | 10,000 | $21.86 | $218,627.00 | (4%) 284.44K to 274.44K | 41% |
| 22-May-20 6:55 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 21-May-20 | Option Exercise | 3,599 | $4.80 | $17,275.20 | 1% 267.24K to 270.84K | |
| 22-May-20 6:55 PM View: | Gasmi Mehdi Director | Adverum Biotechnologies, Inc. (ADVM) | 21-May-20 | Market Option Sale (Planned) | 3,599 | $20.02 | $72,048.00 | 1% 270.84K to 274.44K | (36%) |
